Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

RAF265

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Novartis

Drug class:

BRAF inhibitor, VEGFR-2 inhibitor

Related drugs:

‹

›

RET C634W	Thyroid Gland Medullary Carcinoma	RET C634W	Thyroid Gland Medullary Carcinoma	RAF265 Sensitive: D – Preclinical RAF265 Sensitive : D	RAF265 Sensitive: D – Preclinical RAF265 Sensitive : D
KRAS G12R	Thyroid Gland Medullary Carcinoma	KRAS G12R	Thyroid Gland Medullary Carcinoma	RTB101 + RAF265 Sensitive: D – Preclinical RTB101 + RAF265 Sensitive : D	RTB101 + RAF265 Sensitive: D – Preclinical RTB101 + RAF265 Sensitive : D
BRAF mutation	Thyroid Gland Medullary Carcinoma	BRAF mutation	Thyroid Gland Medullary Carcinoma	RTB101 + RAF265 Sensitive: D – Preclinical RTB101 + RAF265 Sensitive : D	RTB101 + RAF265 Sensitive: D – Preclinical RTB101 + RAF265 Sensitive : D
PTEN mutation	Thyroid Gland Medullary Carcinoma	PTEN mutation	Thyroid Gland Medullary Carcinoma	RTB101 + RAF265 Sensitive: D – Preclinical RTB101 + RAF265 Sensitive : D	RTB101 + RAF265 Sensitive: D – Preclinical RTB101 + RAF265 Sensitive : D
RET mutation	Thyroid Gland Medullary Carcinoma	RET mutation	Thyroid Gland Medullary Carcinoma	RTB101 + RAF265 Sensitive: D – Preclinical RTB101 + RAF265 Sensitive : D	RTB101 + RAF265 Sensitive: D – Preclinical RTB101 + RAF265 Sensitive : D
NRAS mutation	Thyroid Gland Medullary Carcinoma	NRAS mutation	Thyroid Gland Medullary Carcinoma	RTB101 + RAF265 Sensitive: D – Preclinical RTB101 + RAF265 Sensitive : D	RTB101 + RAF265 Sensitive: D – Preclinical RTB101 + RAF265 Sensitive : D
KRAS mutation	Thyroid Gland Medullary Carcinoma	KRAS mutation	Thyroid Gland Medullary Carcinoma	RTB101 + RAF265 Sensitive: D – Preclinical RTB101 + RAF265 Sensitive : D	RTB101 + RAF265 Sensitive: D – Preclinical RTB101 + RAF265 Sensitive : D